Celyad Oncology SA (EBR:CYAD)

Celyad Oncology Statistics

Total Valuation

Celyad Oncology has a market cap or net worth of EUR 13.83 million. The enterprise value is 10.54 million.

Market Cap	13.83M
Enterprise Value	10.54M

Important Dates

The last earnings date was Thursday, September 25, 2025.

Earnings Date	Sep 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Celyad Oncology has 44.76 million shares outstanding. The number of shares has increased by 15.83% in one year.

Current Share Class	44.76M
Shares Outstanding	44.76M
Shares Change (YoY)	+15.83%
Shares Change (QoQ)	-0.07%
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	0.05%
Float	17.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	74.36
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.62
EV / Sales	56.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-55.21

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	10,333
Profits Per Employee	-362,444
Employee Count	19
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.87% in the last 52 weeks. The beta is 1.00, so Celyad Oncology's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	+9.87%
50-Day Moving Average	0.35
200-Day Moving Average	0.45
Relative Strength Index (RSI)	36.73
Average Volume (20 Days)	13,682

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celyad Oncology had revenue of EUR 186,000 and -6.52 million in losses. Loss per share was -0.16.

Revenue	186,000
Gross Profit	174,000
Operating Income	-6.57M
Pretax Income	-6.52M
Net Income	-6.52M
EBITDA	-6.52M
EBIT	-6.57M
Loss Per Share	-0.16

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	93.55%
Operating Margin	-3,532.26%
Pretax Margin	-3,507.53%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Celyad Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.83%
Shareholder Yield	n/a
Earnings Yield	-47.17%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1